胰岛素生物仿制药市场调研报告-主要企业、市场规模、份额及发展趋势

Market Overview - The global biosimilar insulin market is projected to reach $3.329 billion in 2024 and is expected to grow to $8.329 billion by 2031, with a compound annual growth rate (CAGR) of 14.2% from 2025 to 2031 [1] - The Chinese market has shown rapid changes in recent years, with its market size in 2024 being in millions of dollars and expected to increase significantly by 2031 [1] Drivers of Market Growth - The market is primarily driven by the increasing demand for affordable diabetes management solutions due to the rising prevalence of diabetes globally, especially in emerging markets [2] - Biosimilar insulins offer similar therapeutic effects to branded products but at lower prices, making them more accessible to patients and healthcare systems [2] - The expiration of patents for several major insulin products has opened the door for the introduction of biosimilars, further propelling market growth [2] Challenges in the Market - The biosimilar insulin market faces challenges related to regulatory approval processes and market acceptance [2] - Despite having similar components, biosimilars are not identical to their reference biologics, raising concerns about safety and efficacy, particularly for long-term use [2] - Regulatory agencies require rigorous testing and clinical trials to ensure biosimilar insulins meet necessary standards, which may delay market entry [2] - There is resistance from healthcare professionals and patients who may be hesitant to switch from branded insulins to biosimilar options due to unfamiliarity or perceived risks [2] - Competition from other diabetes therapies, such as oral medications and innovative insulin delivery devices, may also impact the growth of the biosimilar insulin market [2] Key Players - Major global players in the biosimilar insulin market include Biocon, Gan&Lee, Wockhardt, Eli Lilly, and Sanofi, with the top three companies holding approximately 70% of the market share [3] Product and Distribution Analysis - The report analyzes the production capacity, output, sales volume, revenue, pricing, and future trends of biosimilar insulin in both global and Chinese markets [4] - Key companies and their product characteristics, specifications, prices, sales volumes, and revenues are highlighted, with a focus on major manufacturers in both markets [4] - The main product types include glargine biosimilar insulin, lispro biosimilar insulin, and others [5] - Distribution channels primarily consist of hospitals, retail pharmacies, and others [5]